Rigel Pharmaceuticals/RIGL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.

Ticker

RIGL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Raul Rodriguez

Employees

147

Headquarters

South san francisco, United States

RIGL Metrics

BasicAdvanced
$172M
Market cap
-
P/E ratio
-$0.11
EPS
1.04
Beta
-
Dividend rate
$172M
1.04149
$1.77
$0.71
1.5M
1.264
1.174
-2.91%
-15.83%
-30.14%
1.425
-7.12%
55.76%
2.47%

What the Analysts think about RIGL

Analyst Ratings

Majority rating from 6 analysts.
Hold

RIGL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-27.79% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$30M
-17.37%
Net income
-$8.2M
-1,271.43%
Profit margin
-27.79%
-1,517.86%

RIGL Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 73.41%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.04
-$0.03
-
-$0.05
-
Expected
-$0.08
-$0.07
-$0.03
-$0.03
-$0.03
Surprise
-48.72%
-57.75%
-
73.41%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Rigel Pharmaceuticals stock?

Rigel Pharmaceuticals (RIGL) has a market cap of $172M as of June 20, 2024.

What is the P/E ratio for Rigel Pharmaceuticals stock?

The price to earnings (P/E) ratio for Rigel Pharmaceuticals (RIGL) stock is 0 as of June 20, 2024.

Does Rigel Pharmaceuticals stock pay dividends?

No, Rigel Pharmaceuticals (RIGL) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next Rigel Pharmaceuticals dividend payment date?

Rigel Pharmaceuticals (RIGL) stock does not pay dividends to its shareholders.

What is the beta indicator for Rigel Pharmaceuticals?

Rigel Pharmaceuticals (RIGL) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Rigel Pharmaceuticals stock price target?

The target price for Rigel Pharmaceuticals (RIGL) stock is $4.53, which is NaN% below the current price of $. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Rigel Pharmaceuticals stock

Buy or sell Rigel Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing